Replibio: Net profit of 401 million yuan in 2025, a year-on-year increase of 33.18%

Sina Finance reports on March 30th that ReP Biopharma announced that its operating income in 2025 was 3.398 billion yuan, an increase of 10.70% year-on-year. Net profit was 401 million yuan, an increase of 33.18% year-on-year. The profit distribution plan approved by the board of directors is to distribute a cash dividend of 4 yuan for every 10 shares to all shareholders based on the total share capital of 4.54 billion shares after deducting 10.6874 million shares held in the repurchase special securities account. No bonus shares will be issued, and no additional shares will be transferred to all shareholders from the capital reserve.